Nancy Chan, MD
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients (NCT03393845) | Nancy Chan, MD | 2018-01-29 |
Track Nancy Chan, MD automatically
Every clearance here is in the API, with alerts when new ones post.